The practice of choosing the next best therapy for patients with relapsed and/or refractory
multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus
regarding the best treatment sequence for RRMM. With the approval of novel proteasome
inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide),
monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies,
multiple combination regimens utilizing these agents are being studied with the goal of …